VIENNA, AUSTRIA - EQS Newswire - March 3, 2020 - AFFiRiS, a
clinical-stage biotechnology company developing novel disease-modifying
specific active immunotherapies (SAITs) for patients with neurodegenerative
diseases, today announces the award of a new patent by the Chinese National
Intellectual Property Administration (CNIPA). The patent covers a group of
AFFITOPEs, including PD01, the Company's lead candidate for the treatment of
early-stage Parkinson's disease patients which is expected to enter clinical
phase 2 in the second half of 2020.

AFFiRiS, which has already
obtained patents in the United States, Europe, Australia, Canada, India, Japan
and South Korea for the same application, thus further expand the geographic
coverage of its intellectual property portfolio thanks to this new patent. In
addition, the newly granted IP adds to AFFiRiS' broad patent position covering
the treatment of Parkinson's disease, and its product candidate PD01, as well
as to its overall body of patents and patent applications, reflecting the
excellent competitive profile in the field of neurodegenerative treatments.

"This new patent
strengthens the position of our lead candidate, PD01, which we will move into
phase 2 of clinical development for the treatment Parkinson's disease, an
indication with an urgent and significant unmet medical need," said Noel
Barrett, Ph.D., AFFiRiS' Chief Executive Officer. "Importantly, the new IP
supports us in the growth of our business in the highly attractive Chinese
market."

AFFiRiS recently received
positive FDA responses to its pre-Investigational New Drug ("IND")
submission for the phase 2 trial with AFFITOPE(R) PD01 in early Parkinson's
disease patients. The active immunotherapy candidate PD01 is based on AFFiRiS'
AFFITOPE(R) technology, which is also covered by this new patent.

The new patent CN 101969989
(also published as WO 2009/103105) describes how AFFiRiS' AFFITOPE(R) compounds
may prevent and/or treat neurodegenerative disorders characterized by
pathological accumulation of alpha-synuclein aggregates, commonly referred to
as synucleinopathies, including Parkinson's disease (PD), Parkinson's disease
with dementia (PDD) and dementia with Lewy bodies (DLB), as well as Multiple
System Atrophy (MSA) or Neurodegeneration with Brain Iron Accumulation type I
(NBIA Type I).

The issuer is solely responsible for the content of this announcement.